Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Simcere Pharmaceutical Group

http://en.simcere.com/

Latest From Simcere Pharmaceutical Group

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

Legislation ASCO

ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer

In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.

ASCO China

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

China Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Jilin Boda Pharmaceutical Co., Ltd.
    • ChinaVax
    • Master Luck Corporation Limited
    • Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
    • Jiangsu Yanshen Biological Technology Stock Co., Ltd.
    • Nanjing Tung Chit Pharmaceutical Co., Ltd.
    • Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
    • Wuhu Zhong Ren Pharmaceutical Co. Ltd.
    • Xiangao Investment Company Ltd.
    • Yantai Medgenn Co. Ltd.
    • Jiangsu Simcere Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register